Ulyanovsk Medico-biological Journal

REVIEWS

Download article

DOI 10.34014/2227-1848-2025-1-6-19

MODERN ASPECTS OF RADIONUCLIDE THERAPY IN THYROID CANCER

P.V. Sychev1, Yu.D. Udalov1,2, E.V. Mayakova1, Yu.A. Kaydash1, I.A. Baryshnikov1

1 Federal Scientific and Clinical Center for Medical Radiology and Oncology, Federal Medical
and Biological Agency, Dimitrovgrad, Russia;

2 Russian State Research Center, A.I. Burnasyan Federal Medical and Biophysical Center, Federal Medical and Biological Agency, Moscow, Russia

 

In the last two decades, the incidence of thyroid cancer has increased by almost 28 %, while at the same time mortality has decreased by more than 23 %. This is due to an increase of pathology detection at an early stage. The most favorable prognosis occurs after surgeries combined with radioactive iodine therapy.

Radioactive iodine therapy can be used both for the ablation of thyroid tissue remnants after subtotal or near-total thyroidectomy for multifocal invasive cancer, and for the treatment of regional and distant metastases of differentiated thyroid cancer. The use of radioactive iodine is validated by: its selective accumulation by thyroid cells and highly differentiated tumors; the possibility to achieve a high absorbed dose in the accumulation site with minimal damage to surrounding tissues; the absence of complications, reversibility of side effects after drug administration.

The article provides a review of domestic and foreign literature on modern and promising areas of radionuclide therapy for thyroid cancer treatment.

Pubmed, eLIBRARY and other databases were used as reference sources.

Key words: radionuclide therapy, thyroid cancer, radioiodine therapy, I-131.

 

Conflict of interest. The authors declare no conflict of interest.

Author contributions

Research concept and design: Udalov Yu.D., Mayakova E.V.

Literature search, data processing: Sychev P.V., Kaydash Yu.A., Baryshnikov I.A.

Data analysis and interpretation: Sychev P.V.

Text writing and editing: Sychev P.V.

 

References

  1. Rumyantsev P.O., Il'in A.A., Rumyantseva U.V., Saenko V.A. Rak shchitovidnoy zhelezy: sovremennye podkhody k diagnostike i lecheniyu [Thyroid cancer: Modern approaches to diagnostics and treatment]. Moscow: GEOTAR-Media; 2009. 448 (in Russian).

  2. Kaprin A.D., Starinskiy V.V., Shakhzadova A.O. Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost' i smertnost') [Malignant neoplasms in Russia in 2021 (morbidity and mortality)]. Moscow: MNIOI imeni P.A. Gertsena − filial FGBU «NMITs radiologii» Minzdrava Rossii; 2022. 252 (in Russian).

  3. Papp S., Asa S.L. When thyroid carcinoma goes bad: a morphological and molecular analysis. Head Neck Pathol. 2015; 9 (1): 16–23. DOI: 10.1007/s12105-015-0619-z.

  4. Valdina E.A. Zabolevaniya shchitovidnoy zhelezy: rukovodstvo [Thyroid diseases: Manual. St Petersburg: Piter; 2006. 368 (in Russian).

  5. Schlumberger M., Leboulleux S. Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrin. 2021; 17 (3):176–188. DOI: 10.1038/s41574-020-00448-z.

  6. Pitoia F., Bueno F., Cross G. Long-term survival and low effective cumulative radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastasis from differentiated thyroid cancer. Clin Nucl Med. 2014; 39 (9): 784–790. DOI:10.1097/RLU.0000000000000507.

  7. Cibas E.S., Ali S.Z. The Bethesda system for reporting thyroid cytopathology. Thyroid. 2009; (19): 11: 1159–1165.

  8. Cibas E.S., Ali S.Z. The 2017 Bethesda System For Reporting Thyroid Cytopathology. Thyroid. 2017; 27: 1341–1346. Available at: http://www.ncbi.nlm.nih.gov/pubmed/29091573 (accessed: September 20, 2024).

  9. Kuta V., Forner D., Azzi J., Curry D., Noel C.W., Munroe K., Bullock M., McDonald T., Taylor S.M., Rigby M.H., Trites J., Johnson-Obaseki S., Corsten M.J. Treatment Choices in Managing Bethesda III and IV Thyroid Nodules: A Canadian Multi-institutional Study. OTO Open. 2021; 5 (2): 2473974X211015937. DOI: 10.1177/2473974X211015937. Available at: https://www.on­kos.com.br/en/post/everything-about-the-bethesda-system/ (accessed: September 20, 2024).

  10. Morrison S.A., Suh H., Hodin R.A. The surgical management of thyroid cancer. Rambam Maimonides Med J. 2014; 5 (2): e0008. DOI: 10.5041/RMMJ.10142.

  11. Medullyarnyy rak shchitovidnoy zhelezy: klinicheskie rekomendatsii [Medullary thyroid cancer: Clinical guidelines]. Moscow: Ministerstvo zdravookhraneniya Rossiyskoy Federatsii; 2020. 47 (in Russian).

  12. Wyszomirska A. Iodine-131 for therapy of thyroid diseases. Physical and biological basis. Nucl Med Rev Cent East Eur. 2012; 15 (2): 120–123.

  13. Evtushenko A.V., Gorchitsa Ya.Yu., Sizov P.A., Smirnov A.A. Sovremennaya taktika khirurgicheskogo lecheniya raka shchitovidnoy zhelezy [Modern surgical modalities for thyroid cancer treatment]. European science. 2018; 4 (36). Avaiable at: https://cyberleninka.ru/article/n/sovremennaya-taktika-hirurgicheskogo-lecheniya-raka-schitovidnoy-zhelezy (accessed: February 20, 2023) (in Russian).

  14. Sawka A.M., Ibrahim-Zada I., Galacgac P., Tsang R.W., Brierley J.D., Ezzat S., Goldstein D.P. Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review. Thyroid. 2010; 20 (10): 1129–1138. DOI: 10.1089/thy.2010.0055.

  15. Pacini F., Schlumberger M., Dralle H., Elisei R., Smit J.W., Wiersinga W.; European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006; 154 (6): 787–803. DOI: 10.1530/eje.1.02158. Erratum in: Eur J Endocrinol. 2006; 155 (2): 385.

  16. Schmidbauer B., Menhart K., Hellwig D., Grosse J. Differentiated thyroid cancer – treatment: state of the art. Int J Mol Sci. 2017; 18 (6): 1292. DOI: 10.3390/ijms18061292.

  17. Haugen B.R., Alexander E.K., Bible K.C., Doherty G.M., Mandel S.J., Nikiforov Y.E., Pacini F., Randolph G.W., Sawka A.M., Schlumberger M., Schuff K.G., Sherman S.I., Sosa J.A., Steward D.L., Tuttle R.M., Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26 (1): 1–133. DOI: 10.1089/thy.2015.0020.

  18. Buffet C., Ghander C., le Marois E., Leenhardt L. Indications for radioiodine administration in follicular-derived thyroid cancer. Ann Endocrinol (Paris). 2015; 76 (Suppl. 1): 1S2–1S7. DOI:10.1016/S0003-4266(16)30008-7.

  19. Castagna M.G., Cantara S., Pacini F. Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients. J Endocrinol Invest. 2016; 39 (10): 1087–1094. DOI: 10.1007/s40618-016-0503-z.

  20.  Kuo S.F. The role of radioactive iodine therapy in young patients with papillary thyroid cancer. Clin. Nucl. Med. 2009; 15 (1): 4–6.

  21. Mihailovic J., Stefanovic L., Malesevic M. Differentiated thyroid carcinoma with distant metastases: probability of survival and its predicting factors. Cancer Biother Radiopharm. 2007; 22 (2): 250–255.

  22. Novikova A.A., Zuy V.S., Solov'ev V.I., Semkina E.N. Effektivnost' radioyodterapii pri lechenii raka shchitovidnoy zhelezy v Smolenskoy oblasti (2016–2018 gg.) [Efficiency of radioiodine therapy for thyroid cancer treatment in the Smolensk region in 2016–2018]. Smolenskiy meditsinskiy al'manakh. 2019; 1: 214–216 (in Russian).

  23. Sawka A.M., Brierley J.D., Tsang R.W., Thabane L., Rotstein L., Gafni A., Straus S., Goldstein D.P. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2008; 37 (2): 457–480. DOI: 10.1016/j.ecl.2008.02.007.

  24. Hay I.D. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006; 94 (8): 692–700. DOI: 10.1002/jso.20696.

  25. Reiners C., Dietlein M., Luster M. Radio-iodine therapy in differentiated thyroid cancer: indications and procedures. Best Pract Res Clin Endocrinol Metab. 2008; 22 (6): 989–1007. DOI: 10.1016/j.beem.2008.09.013.

  26. Perrino M., Vannucchi G., Colombo C. Papillary thyroid cancers ≤2 cm: outcome predictors and impact of surgical and radiometabolic treatments. Arch. Surg. 2008; 135 (2): 45–52.

  27. Küçük N.O., Tari P., Tokmak E., Aras G. Treatment for microcarcinoma of the thyroid-clinical experience. Clin Nucl Med. 2007; 32 (4): 279–281. DOI: 10.1097/01.rlu.0000257272.90126.3d.

  28. Coerts H.I., de Keizer B., Marlowe R.J., Verburg F.A. Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies. Eur J Endocrinol. 2023; 188 (2): lvad006. DOI: 10.1093/ejendo/lvad006.

  29. Carpi A., Bianchi R., Zucchelli G.C., Del Corso L., Levanti C., Cocci L.F., Giannessi D., Mariani G. Effect of endogenous thyroid stimulating hormone levels on the secretion of thyroid hormones in man. Acta Endocrinol (Copenh). 1979; 92 (1): 73–84. DOI: 10.1530/acta.0.0920073.

  30. Bel'tsevich D.G., Vanushko V.E., Rumyantsev P.O., Mel'nichenko G.A., Kuznetsov N.S., Abrosimov A.Yu., Polyakov V.G., Mudunov A.M., Podvyaznikov S.O., Romanov I.S., Polyakov A.P., Sleptsov I.V., Chernikov R.A., Vorob'ev S.L., Fadeev V.V. Rossiyskie klinicheskie rekomendatsii po diagnostike i lecheniyu vysokodifferentsirovannogo raka shchitovidnoy zhelezy u vzroslykh, 2017 god [Russian clinical practice guidelines for differentiated thyroid cancer diagnosis and treatment]. Endokrinnaya khirurgiya. 2017; 11 (1): 6–27. DOI: 10.14341/serg201716-27 (in Russian).

  31. Sawka A.M., Ibrahim-Zada I., Galacgac P., Tsang R.W., Brierley J.D., Ezzat S., Goldstein D.P. Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review. Thyroid. 2010; 20 (10): 1129–1138. DOI: 10.1089/thy.2010.0055.

  32. Incerti C. Recombinant human thyroid-stimulating hormone (rhTSH): clinical development. J Endocrinol Invest. 1999; 22 (Suppl. 11): 8–16.

  33. Duntas L.H., Tsakalakos N., Grab-Duntas B., Kalarritou M., Papadodima E. The use of recombinant human thyrotropin (Thyrogen) in the diagnosis and treatment of thyroid cancer. Hormones (Athens). 2003; 2 (3): 169–174. DOI: 10.14310/horm.2002.1197.

  34. Shurinov A.Yu., Krylov V.V., Borodavina E.V. Radioyodablatsiya pri rake shchitovidnoy zhelezy. Istoricheskie i sovremennye aspekty. Obzor literatury [Radioiodine ablation for thyroid cancer. Historical and modern aspects. Literature review]. Onkologicheskiy zhurnal: luchevaya diagnostika, luchevaya terapiya. 2021; 4 (4): 9–19. DOI: 10.37174/2587-7593-2021-4-4-9-19 (in Russian).

  35. Silberstein E.B. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med. 2007; 48 (7): 1043–1046. DOI: 10.2967/jnumed.107.040311.

  36. Kaliszewski K., Wojtczak B., Strutyńska-Karpińska M., Łukieńczuk T., Forkasiewicz Z., Domosławs­ki P. Incidental and non-incidental thyroid microcarcinoma. Oncol Lett. 2016; 12 (1): 734–740. DOI: 10.3892/ol.2016.4640.

  37. Winter J., Winter M., Krohn T., Heinzel A., Behrendt F.F., Tuttle R.M., Mottaghy F.M., Verburg F.A. Patients with high-risk differentiated thyroid cancer have a lower I-131 ablation success rate than low-risk ones in spite of a high ablation activity. Clin Endocrinol (Oxf). 2016; 85 (6): 926-931. DOI: 10.1111/cen.13123.

  38. Zhang Y., Wang C., Zhang X., Li H., Li X., Lin Y. 30mCi radioactive iodine achieving comparative excellent response in intermediate/high Z risk nonmetastatic papillary thyroid cancer: a propensity score matching study. Endocrine. 2018; 62 (3): 655–662. DOI: 10.1007/s12020-018-1724-z.

  39. Iizuka Y., Katagiri T., Ogura K., Mizowaki T. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer. Ann Nucl Med. 2019; 33 (7): 495–501. DOI: 10.1007/s12149-019-01357-6.

  40. Pilli T., Brianzoni E., Capoccetti F., Castagna M.G., Fattori S., Poggiu A., Rossi G., Ferretti F.,Guarino E., Burroni L., Vattimo A., Cipri C., Pacini F. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab. 2007; 92 (9): 3542–3546. DOI: 10.1210/jc.2007-0225.

  41. James D.L., Ryan É.J., Davey M.G., Quinn A.J., Heath D.P., Garry S.J., Boland M.R., Young O., Lowery A.J., Kerin M.J. Radioiodine Remnant Ablation for Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2021; 147 (6): 544–552. DOI: 10.1001/jamaoto.2021.0288.

  42. Caglar M., Bozkurt F.M., Akca C.K., Vargol S.E., Bayraktar M., Ugur O., Karaağaoğlu E. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer. Nucl Med Commun. 2012; 33 (3): 268–274. DOI: 10.1097/MNM.0b013e32834ec5d6.

  43. Vlasova O.P., Klepov A.N., Matusevich E.S., Kurachenko Yu.A. Razvitie tekhnologii individual'nogo dozimetricheskogo planirovaniya radioyodterapii zabolevaniy shchitovidnoy zhelezy [Advancements in technology for individual dosimetric planning of radioiodine therapy for thyroid diseases]. Al'manakh klinicheskoy meditsiny. 2008; 17 (1): 303–306 (in Russian).

  44. Van der Horst-Schrivers A.N., Sluiter W.J., Muller Kobold A.C., Wolffenbuttel B.H., Plukker J.T., Biss­chop P.H., de Klerk J.M., Al. Younis I., Lips P., Smit J.W., Brouwers A.H., Links T.P. Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success – an observational study. PLoS One. 2015; 10 (3): e0120184. DOI: 10.1371/journal.pone.0120184.

  45. Paladino S., Melillo R.M. Editorial: Novel Mechanism of Radioactive Iodine Refractivity in Thyroid Cancer. J Natl Cancer Inst. 2017; 109 (12). DOI: 10.1093/jnci/djx106.

  46. Ravera S., Reyna-Neyra A., Ferrandino G., Amzel L.M., Carrasco N. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications. Annu Rev Physiol. 2017; 79: 261–289. DOI: 10.1146/annurev-physiol-022516-034125.

  47. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013; 13 (3): 184–199. DOI: 10.1038/nrc3431.

  48. Riesco-Eizaguirre G., Gutiérrez-Martínez P., García-Cabezas M.A., Nistal M., Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer. 2006; 13 (1): 257–269. DOI: 10.1677/erc.1.01119.

  49. Schlumberger M., Brose M., Elisei R., Leboulleux S., Luster M., Pitoia F., Pacini F. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014; 2 (5): 356–358. DOI: 10.1016/S2213-8587(13)70215-8.

  50. Bolotina L.V., Vladimirova L.Yu., Den'gina N.V., Novik A.V., Romanov I.S. Prakticheskie rekomendatsii po lecheniyu zlokachestvennykh opukholey golovy i shei [Best practices for head and neck malignant tumor treatment]. Zlokachestvennye opukholi. 2020; 10 (3S2-1): 92–107. DOI 10.18027/2224-5057-2020-10-3s2-06 (in Russian).

  51. Haugen B.R. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol. 1999; 16 (1): 34–41. DOI: 10.1002/(sici)1098-2388(199901/02)16:1<34::aid-ssu7>3.0.co;2-2. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27581851 (accessed: May 18, 2024).

  52. Borodavina E.V., Krylov V.V., Isaev P.A., Shurinov A.Yu., Rodichev A.A. Istoricheskie aspekty i sovremennye kontseptsii v lechenii bol'nykh differentsirovannym rakom shchitovidnoy zhelezy, refrakternym k terapii radioaktivnym yodom [Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapy]. Opukholi golovy i shei. 2021; 11 (4): 119–130. DOI: 10.17650/2222-1468-2021-11-4-119-130 (in Russian).

Received October 01, 2024; accepted October 28, 2024.

 

Information about the authors

Sychev Petr Vladimirovich, Head of the Nuclear Medicine Center, Radiologist, Federal Scientific and Clinical Center for Medical Radiology and Oncology, Federal Medical and Biological Agency. 433510, Russia, Ulyanovsk region, Dimitrovgrad, Kurchatov St., 5v; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0003-3965-4661

Udalov Yuriy Dmitrievich, Doctor of Sciences (Medicine), Associate Professor, Director General, Federal Scientific and Clinical Center for Medical Radiology and Oncology, Federal Medical and Biological Agency. 433510, Russia, Ulyanovsk region, Dimitrovgrad, Kurchatov St., 5v; Professor, Chair of Therapy, Russian State Research Center, A.I. Burnasyan Federal Medical and Biophysical Center, Federal Medical and Biological Agency 123182, Russia, Moscow, Marshal Novikov St., 23; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.,ORCIDID: https://orcid.org/0000-0002-9739-8478

Mayakova Elena Viktorovna, Deputy Director General for Medical Affairs, Chief Physician, Federal Scientific and Clinical Center for Medical Radiology and Oncology, Federal Medical and Biological Agency. 433510, Russia, Ulyanovsk region, Dimitrovgrad, Kurchatov St., 5v; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0001-5551-818Х 

Kaydash Yuliya Aleksandrovna, Head of the Radionuclide Therapy Department, Center for Nuclear Medicine, Radiologist, Federal Scientific and Clinical Center for Medical Radiology and Oncology, Federal Medical and Biological Agency. 433510, Russia, Ulyanovsk region, Dimitrovgrad, Kurchatov St., 5v; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0001-9957-1871

Baryshnikov Ivan Anatol'evich, Radiologist, Topometric Preparation Unit, Proton and Photon Center, Federal Scientific and Clinical Center for Medical Radiology and Oncology, Federal Medical and Biological Agency. 433510, Russia, Ulyanovsk region, Dimitrovgrad, Kurchatov St., 5v; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0002-8903-6012

 

For citation

Sychev P.V., Udalov Yu.D., Mayakova E.V., Kaydash Yu.A., Baryshnikov I.A. Sovremennye aspekty radionuklidnoy terapii raka shchitovidnoy zhelezy [Modern aspects of radionuclide therapy in thyroid cancer]. Ul'yanovskiy mediko-biologicheskiy zhurnal. 2025; 1: 6–19. DOI: 10.34014/2227-1848-2025-1-6-19
(in Russian).

 

Скачать статью

УДК 616.441-006.04

DOI 10.34014/2227-1848-2025-1-6-19

СОВРЕМЕННЫЕ АСПЕКТЫ РАДИОНУКЛИДНОЙ ТЕРАПИИ РАКА ЩИТОВИДНОЙ ЖЕЛЕЗЫ

П.В. Сычев1, Ю.Д. Удалов1,2, Е.В. Маякова1, Ю.А. Кайдаш1, И.А. Барышников1

1 ФГБУ «Федеральный научно-клинический центр медицинской радиологии и онкологии» Федерального медико-биологического агентства, г. Димитровград, Россия;

2 ФГБУ «Государственный научный центр Российской Федерации – Федеральный медицинский биофизический центр имени А.И. Бурназяна» Федерального медико-биологического агентства, г. Москва, Россия

 

В последние два десятилетия отмечен рост заболеваемости раком щитовидной железы почти на 28 % при одновременном снижении смертности более чем на 23 %. Это связано с повышением выявляемости патологии на ранних стадиях, при которых наиболее благоприятный прогноз имеет место после хирургического лечения в комплексе с терапией радиоактивным йодом.

Применение радиойода показано как для абляции остатков ткани щитовидной железы после субтотального или околототального удаления органа по поводу многофокусного инвазивного рака, так и для лечения регионарных и отдаленных метастазов дифференцированного рака щитовидной железы. Применение радиоактивного йода обосновано его избирательным накоплением клетками щитовидной железы и высокодифференцированных опухолей; возможностью достижения высокой поглощенной дозы в очаге накопления при минимальном повреждающем воздействии на окружающие ткани; отсутствием осложнений, обратимостью побочных реакций при введении лечебных активностей.

В статье проведен обзор отечественной и зарубежной литературы по вопросам современных и перспективных направлений лечения больных раком щитовидной железы методом радионуклидной терапии.

В качестве источников информации использовались данные электронных библиотек Pubmed, eLIBRARY и др.

Ключевые слова: радионуклидная терапия, рак щитовидной железы, радиойодтерапия, I-131.

 

Конфликт интересов. Авторы заявляют об отсутствии конфликта интересов.

Вклад авторов

Концепция и дизайн исследования: Удалов Ю.Д., Маякова Е.В.

Литературный поиск, обработка материала: Сычев П.В., Кайдаш Ю.А., Барышников И.А.

Анализ и интерпретация данных: Сычев П.В.

Написание и редактирование текста: Сычев П.В.

 

Литература

  1. Румянцев П.О., Ильин А.А., Румянцева У.В., Саенко В.А. Рак щитовидной железы: современные подходы к диагностике и лечению. М.: ГЭОТАР-Медиа; 2009. 448.

  2. Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М.: МНИОИ имени П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2022. 252.

  3. Papp S., Asa S.L. When thyroid carcinoma goes bad: a morphological and molecular analysis. Head Neck Pathol. 2015; 9 (1): 16–23. DOI: 10.1007/s12105-015-0619-z.

  4. Валдина Е.А. Заболевания щитовидной железы: руководство. СПб.: Питер; 2006. 368.

  5. Schlumberger M., Leboulleux S. Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrin. 2021; 17 (3):176–188. DOI: 10.1038/s41574-020-00448-z.

  6. Pitoia F., Bueno F., Cross G. Long-term survival and low effective cumulative radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastasis from differentiated thyroid cancer. Clin Nucl Med. 2014; 39 (9): 784–790. DOI:10.1097/RLU.0000000000000507.

  7. Cibas E.S., Ali S.Z. The Bethesda system for reporting thyroid cytopathology. Thyroid. 2009; (19): 11: 1159–1165.

  8. Cibas E.S., Ali S.Z. The 2017 Bethesda System For Reporting Thyroid Cytopathology. Thyroid. 2017; 27: 1341–1346. URL: http://www.ncbi.nlm.nih.gov/pubmed/29091573 (дата обращения: 20.09.2024).

  9. Kuta V., Forner D., Azzi J., Curry D., Noel C.W., Munroe K., Bullock M., McDonald T., Taylor S.M., Rigby M.H., Trites J., Johnson-Obaseki S., Corsten M.J. Treatment Choices in Managing Bethesda III and IV Thyroid Nodules: A Canadian Multi-institutional Study. OTO Open. 2021; 5 (2): 2473974X211015937. DOI: 10.1177/2473974X211015937. URL: https://www.onkos.com.br/en/post/everything-about-the-bethesda-system/ (дата обращения: 20.09.2024).

  10. Morrison S.A., Suh H., Hodin R.A. The surgical management of thyroid cancer. Rambam Maimonides Med J. 2014; 5 (2): e0008. DOI: 10.5041/RMMJ.10142.

  11. Медуллярный рак щитовидной железы: клинические рекомендации. М.: Министерство здравоохранения Российской Федерации; 2020. 47.

  12. Wyszomirska A. Iodine-131 for therapy of thyroid diseases. Physical and biological basis. Nucl Med Rev Cent East Eur. 2012; 15 (2): 120–123.

  13. Евтушенко А.В., Горчица Я.Ю., Сизов П.А., Смирнов А.А. Современная тактика хирургического лечения рака щитовидной железы. European science. 2018; 4 (36). URL: https://cyberleninka.ru/article/n/sovremennaya-taktika-hirurgicheskogo-lecheniya-raka-schitovidnoy-zhelezy (дата обращения: 20.02.2023).

  14. Sawka A.M., Ibrahim-Zada I., Galacgac P., Tsang R.W., Brierley J.D., Ezzat S., Goldstein D.P. Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review. Thyroid. 2010; 20 (10): 1129–1138. DOI: 10.1089/thy.2010.0055.

  15. Pacini F., Schlumberger M., Dralle H., Elisei R., Smit J.W., Wiersinga W.; European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006; 154 (6): 787–803. DOI: 10.1530/eje.1.02158. Erratum in: Eur J Endocrinol. 2006; 155 (2): 385.

  16. Schmidbauer B., Menhart K., Hellwig D., Grosse J. Differentiated thyroid cancer – treatment: state of the art. Int J Mol Sci. 2017; 18 (6): 1292. DOI: 10.3390/ijms18061292.

  17. Haugen B.R., Alexander E.K., Bible K.C., Doherty G.M., Mandel S.J., Nikiforov Y.E., Pacini F., Randolph G.W., Sawka A.M., Schlumberger M., Schuff K.G., Sherman S.I., Sosa J.A., Steward D.L., Tuttle R.M., Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26 (1): 1–133. DOI: 10.1089/thy.2015.0020.

  18. Buffet C., Ghander C., le Marois E., Leenhardt L. Indications for radioiodine administration in follicular-derived thyroid cancer. Ann Endocrinol (Paris). 2015; 76 (Suppl. 1): 1S2–1S7. DOI:10.1016/S0003-4266(16)30008-7.

  19. Castagna M.G., Cantara S., Pacini F. Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients. J Endocrinol Invest. 2016; 39 (10): 1087–1094. DOI: 10.1007/s40618-016-0503-z.

  20. Kuo S.F. The role of radioactive iodine therapy in young patients with papillary thyroid cancer. Clin. Nucl. Med. 2009; 15 (1): 4–6.

  21. Mihailovic J., Stefanovic L., Malesevic M. Differentiated thyroid carcinoma with distant metastases: probability of survival and its predicting factors. Cancer Biother Radiopharm. 2007; 22 (2): 250–255.

  22. Новикова А.А., Зуй В.С., Соловьев В.И., Семкина Е.Н. Эффективность радиойодтерапии при лечении рака щитовидной железы в Смоленской области (2016–2018 гг.). Смоленский медицинский альманах. 2019; 1: 214–216.

  23. Sawka A.M., Brierley J.D., Tsang R.W., Thabane L., Rotstein L., Gafni A., Straus S., Goldstein D.P. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2008; 37 (2): 457–480. DOI: 10.1016/j.ecl.2008.02.007.

  24. Hay I.D. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006; 94 (8): 692–700. DOI: 10.1002/jso.20696.

  25. Reiners C., Dietlein M., Luster M. Radio-iodine therapy in differentiated thyroid cancer: indications and procedures. Best Pract Res Clin Endocrinol Metab. 2008; 22 (6): 989–1007. DOI: 10.1016/j.beem.2008.09.013.

  26. Perrino M., Vannucchi G., Colombo C. Papillary thyroid cancers ≤2 cm: outcome predictors and impact of surgical and radiometabolic treatments. Arch. Surg. 2008; 135 (2): 45–52.

  27. Küçük N.O., Tari P., Tokmak E., Aras G. Treatment for microcarcinoma of the thyroid-clinical experience. Clin Nucl Med. 2007; 32 (4): 279–281. DOI: 10.1097/01.rlu.0000257272.90126.3d.

  28. Coerts H.I., de Keizer B., Marlowe R.J., Verburg F.A. Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies. Eur J Endocrinol. 2023; 188 (2): lvad006. DOI: 10.1093/ejendo/lvad006.

  29. Carpi A., Bianchi R., Zucchelli G.C., Del Corso L., Levanti C., Cocci L.F., Giannessi D., Mariani G. Effect of endogenous thyroid stimulating hormone levels on the secretion of thyroid hormones in man. Acta Endocrinol (Copenh). 1979; 92 (1): 73–84. DOI: 10.1530/acta.0.0920073.

  30. Бельцевич Д.Г., Ванушко В.Э., Румянцев П.О., Мельниченко Г.А., Кузнецов Н.С., Абросимов А.Ю., Поляков В.Г., Мудунов А.М., Подвязников С.О., Романов И.С., Поляков А.П., Слепцов И.В., Черников Р.А., Воробьев С.Л., Фадеев В.В. Российские клинические рекомендации по диагностике и лечению высокодифференцированного рака щитовидной железы у взрослых, 2017 год. Эндокринная хирургия. 2017; 11 (1): 6–27. DOI: 10.14341/serg201716-27.

  31. Sawka A.M., Ibrahim-Zada I., Galacgac P., Tsang R.W., Brierley J.D., Ezzat S., Goldstein D.P. Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review. Thyroid. 2010; 20 (10): 1129–1138. DOI: 10.1089/thy.2010.0055.

  32. Incerti C. Recombinant human thyroid-stimulating hormone (rhTSH): clinical development. J Endocrinol Invest. 1999; 22 (Suppl. 11): 8–16.

  33. Duntas L.H., Tsakalakos N., Grab-Duntas B., Kalarritou M., Papadodima E. The use of recombinant human thyrotropin (Thyrogen) in the diagnosis and treatment of thyroid cancer. Hormones (Athens). 2003; 2 (3): 169–174. DOI: 10.14310/horm.2002.1197.

  34. Шуринов А.Ю., Крылов В.В., Бородавина Е.В. Радиойодаблация при раке щитовидной железы. Исторические и современные аспекты. Обзор литературы. Онкологический журнал: лучевая диагностика, лучевая терапия. 2021; 4 (4): 9–19. DOI: 10.37174/2587-7593-2021-4-4-9-19.

  35. Silberstein E.B. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med. 2007; 48 (7): 1043–1046. DOI:10.2967/jnumed.107.040311.

  36. Kaliszewski K., Wojtczak B., Strutyńska-Karpińska M., Łukieńczuk T., Forkasiewicz Z., Domosławski P. Incidental and non-incidental thyroid microcarcinoma. Oncol Lett. 2016; 12 (1): 734–740. DOI: 10.3892/ol.2016.4640.

  37. Winter J., Winter M., Krohn T., Heinzel A., Behrendt F.F., Tuttle R.M., Mottaghy F.M., Verburg F.A. Patients with high-risk differentiated thyroid cancer have a lower I-131 ablation success rate than low-risk ones in spite of a high ablation activity. Clin Endocrinol (Oxf). 2016; 85 (6): 926-931. DOI: 10.1111/cen.13123.

  38. Zhang Y., Wang C., Zhang X., Li H., Li X., Lin Y. 30mCi radioactive iodine achieving comparative excellent response in intermediate/high Z risk nonmetastatic papillary thyroid cancer: a propensity score matching study. Endocrine. 2018; 62 (3): 655–662. DOI: 10.1007/s12020-018-1724-z.

  39. Iizuka Y., Katagiri T., Ogura K., Mizowaki T. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer. Ann Nucl Med. 2019; 33 (7): 495–501. DOI: 10.1007/s12149-019-01357-6.

  40. Pilli T., Brianzoni E., Capoccetti F., Castagna M.G., Fattori S., Poggiu A., Rossi G., Ferretti F., Guarino E., Burroni L., Vattimo A., Cipri C., Pacini F. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab. 2007; 92 (9): 3542–3546. DOI: 10.1210/jc.2007-0225.

  41. James D.L., Ryan É.J., Davey M.G., Quinn A.J., Heath D.P., Garry S.J., Boland M.R., Young O., Lowery A.J., Kerin M.J. Radioiodine Remnant Ablation for Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2021; 147 (6): 544–552. DOI: 10.1001/jamaoto.2021.0288.

  42. Caglar M., Bozkurt F.M., Akca C.K., Vargol S.E., Bayraktar M., Ugur O., Karaağaoğlu E. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer. Nucl Med Commun. 2012; 33 (3): 268–274. DOI: 10.1097/MNM.0b013e32834ec5d6.

  43. Власова О.П., Клепов А.Н., Матусевич Е.С., Кураченко Ю.А. Развитие технологии индивидуального дозиметрического планирования радиойодтерапии заболеваний щитовидной железы. Альманах клинической медицины. 2008; 17 (1): 303–306.

  44. Van der Horst-Schrivers A.N., Sluiter W.J., Muller Kobold A.C., Wolffenbuttel B.H., Plukker J.T., Bisschop P.H., de Klerk J.M., Al. Younis I., Lips P., Smit J.W., Brouwers A.H., Links T.P. Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success – an observational study. PLoS One. 2015; 10 (3): e0120184. DOI: 10.1371/journal.pone.0120184.

  45. Paladino S., Melillo R.M. Editorial: Novel Mechanism of Radioactive Iodine Refractivity in Thyroid Cancer. J Natl Cancer Inst. 2017; 109 (12). DOI: 10.1093/jnci/djx106.

  46. Ravera S., Reyna-Neyra A., Ferrandino G., Amzel L.M., Carrasco N. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications. Annu Rev Physiol. 2017; 79: 261–289. DOI: 10.1146/annurev-physiol-022516-034125.

  47. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013; 13 (3): 184–199. DOI: 10.1038/nrc3431.

  48. Riesco-Eizaguirre G., Gutiérrez-Martínez P., García-Cabezas M.A., Nistal M., Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer. 2006;

    13 (1): 257–269. DOI: 10.1677/erc.1.01119.

  49. Schlumberger M., Brose M., Elisei R., Leboulleux S., Luster M., Pitoia F., Pacini F. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014; 2 (5): 356–358. DOI: 10.1016/S2213-8587(13)70215-8.

  50. Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В., Новик А.В., Романов И.С. Практические рекомендации по лечению злокачественных опухолей головы и шеи. Злокачественные опухоли. 2020; 10 (3S2-1): 92–107. DOI 10.18027/2224-5057-2020-10-3s2-06.

  51. Haugen B.R. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol. 1999; 16 (1): 34–41. DOI: 10.1002/(sici)1098-2388(199901/02)16:1<34::aid-ssu7>3.0.co;2-2. URL: https://www.ncbi.nlm.nih.gov/pubmed/27581851 (дата обращения: 18.05.2024).

  52. Бородавина Е.В., Крылов В.В., Исаев П.А., Шуринов А.Ю., Родичев А.А. Исторические аспекты и современные концепции в лечении больных дифференцированным раком щитовидной железы, рефрактерным к терапии радиоактивным йодом. Опухоли головы и шеи. 2021; 11 (4): 119–130. DOI: 10.17650/2222-1468-2021-11-4-119-130.

Поступила в редакцию 01.10.2024; принята 21.10.2024.

 

Авторский коллектив

Сычев Петр Владимирович – начальник Центра ядерной медицины, врач-радиолог, ФГБУ «Федеральный научно-клинический центр медицинской радиологии и онкологии» Федерального медико-биологического агентства. 433510, Россия, Ульяновская область, г. Димитровград, ул. Курчатова, 5в; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0003-3965-4661

Удалов Юрий Дмитриевич – доктор медицинских наук, доцент, генеральный директор, ФГБУ «Федеральный научно-клинический центр медицинской радиологии и онкологии» Федерального медико-биологического агентства. 433510, Россия, Ульяновская область, г. Димитровград, ул. Курчатова, 5в; профессор кафедры терапии, ФГБУ «Государственный научный центр Российской Федерации – Федеральный медицинский биофизический центр имени А.И. Бурназяна» ФМБА России. 123182, Россия, г. Москва, ул. Маршала Новикова, 23; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCIDID: https://orcid.org/0000-0002-9739-8478

Маякова Елена Викторовна – заместитель генерального директора по медицинской части – главный врач, ФГБУ «Федеральный научно-клинический центр медицинской радиологии и онкологии» Федерального медико-биологического агентства. 433510, Россия, Ульяновская область, г. Димитровград, ул. Курчатова, 5в; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0001-5551-818X

Кайдаш Юлия Александровна – заведующий отделением радионуклидной терапии Центра ядерной медицины, врач-радиолог, ФГБУ «Федеральный научно-клинический центр медицинской радиологии и онкологии» Федерального медико-биологического агентства. 433510, Россия, Ульяновская область, г. Димитровград, ул. Курчатова, 5в; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0001-9957-1871

Барышников Иван Анатольевич – врач-рентгенолог блока топометрической подготовки Протонного и фотонного центра, ФГБУ «Федеральный научно-клинический центр медицинской радиологии и онкологии» Федерального медико-биологического агентства. 433510, Россия, Ульяновская область, г. Димитровград, ул. Курчатова, 5в; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0002-8903-6012

 

Образец цитирования

Сычев П.В., Удалов Ю.Д., Маякова Е.В., Кайдаш Ю.А., Барышников И.А. Современные аспекты радионуклидной терапии рака щитовидной железы. Ульяновский медико-биологический журнал. 2025; 1: 6–19. DOI: 10.34014/2227-1848-2025-1-6-19.